Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Apr 23;18(1):46.
doi: 10.1186/s13045-025-01695-1.

CD20 xCD3 bispecific antibodies for large B cell lymphoma: latest updates from 2024 ASH annual meeting

V Tomarchio  1   2 , L Rigacci  3   4 , O Annibali  3   4
Affiliations
Review

CD20 xCD3 bispecific antibodies for large B cell lymphoma: latest updates from 2024 ASH annual meeting

V Tomarchio et al. J Hematol Oncol. .

Abstract

Bispecific antibodies (BsAbs) represent an innovative class of off-the-shelf T-cell redirecting agents and are considered among the most promising immunotherapeutic strategies for the treatment of lymphoma. Notably, anti-CD20 × CD3 BsAbs have exhibited substantial monotherapy efficacy in patients with heavily pretreated B-cell non-Hodgkin lymphoma (B-NHL), showing a tolerable toxicity profile predominantly associated with T-cell activation-related side effects. In this study, we summarized several latest reports on CD20 × CD3 bsAbs for the therapy of Large B Cell Lymphoma (LBCL), also in first line, from the ASH 2024 annual meeting (ASH 2024).

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval and consent to participate: This is not applicable for this summary. Competing interests: The authors declare no competing interests.

References

    1. Falchi L, Offner F, de Vos S, Brody J, Cordoba R, Linton K, Belada D. Fixed-Duration Epcoritamab + R-CHOP induces high complete response rates in patients with previously untreated diffuse large B-Cell lymphoma Withhigh-Risk features: Long-Term results from the Epcore NHL-2 trial. Blood. 2024;144:581. - PubMed
    1. Minson A, Verner E, Giri P, Butler J, Janowski W, Cheah CY, Dickinson MJ. A randomized phase 2, Investigator-Led trial of Glofitamab-R-CHOP or Glofitamab-Polatuzumab Vedotin-R-CHP (COALITION) in younger patients with high burden, high-Risk large B-Cell lymphoma demonstrates safety, uncompromised chemotherapy intensity, a high rate of durable remissions, and unique FDG-PET response characteristics. Blood. 2024;144:582.
    1. Morschhauser F, Belada D, Duell J, Jurczak W, Kim TM, Kim WS, Woei-A-Jin S. Epcore DLBCL-3 first disclosure: Fixed-Duration Epcoritamab monotherapy in older (≥ 75 y), Anthracycline-Ineligible patients with previously untreated large B-Cell lymphoma. Blood. 2024;144:867. - PubMed
    1. Leslie LA, Cheah CY, Morschhauser F, Darrah JM, Brody J, Belada D, Karimi YH. Fixed-Duration Epcoritamab + R-Mini-CHOP in patients with previously untreated diffuse large B-Cell lymphoma ineligible for Full-Dose R-CHOP: updated results from arm 8 of the Epcore NHL-2 trial. Blood. 2024;144:3106.
    1. Allan JN, Crombie JL, Matasar M, Topp MS, Walewski J, Kim TM, Arnason JE. Long-Term efficacy and safety of Odronextamab in relapsed/refractory diffuse large B-Cell lymphoma (DLBCL): pooled analysis from the ELM-1 and ELM-2 studies. Blood. 2024;144:3118.

MeSH terms

LinkOut - more resources